Surgery in oligometastatic NSCLC patients in the targeted therapy era [0.03%]
靶向治疗时代下寡转移非小细胞肺癌患者的手术治疗
Qi Zhang,Yi-Long Wu
Qi Zhang
More than 50% of NSCLC patients present with metastatic disease at first diagnosis, with a median survival of 8-11 months. However, selected patients with oligometastatic disease who receive appropriate local therapy for both the primary le...
Navigational bronchoscopy at a community hospital: clinical and economic outcomes [0.03%]
导航支气管镜在社区医院的临床和经济效益评估
Susan K Garwood,Pam ClenDening,Nathanael D Hevelone et al.
Susan K Garwood et al.
Aim: To evaluate the clinical and financial impact of introducing electromagnetic navigation bronchoscopy (ENB) at a community center. Methods: ...
First-line treatment of nonsquamous NSCLC using gemcitabine: a retrospective study of real-life practice [0.03%]
吉西他滨一线治疗非鳞状细胞非小细胞肺癌的回顾性研究
Filip Kohutek,Miroslava Stratena,Andrej Rosik et al.
Filip Kohutek et al.
We present results of retrospective real-life data of nonsquamous lung cancer patients treated in first-line (platinum-based chemotherapy with gemcitabine without bevacizumab). 56 patients with satisfactory performance status for cytotoxic ...
Case Reports
Lung cancer management. 2016 Nov;5(3):123-130. DOI:10.2217/lmt-2016-0011 2016
Cost-effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression [0.03%]
根据PD-L1表达水平评估免疫检查点抑制剂治疗NSCLC的性价比
Pedro Aguiar Jr,Luke A Perry,Gilberto L Lopes Jr
Pedro Aguiar Jr
Measurement of quality of life in second-line patients with advanced NSCLC without targetable mutations: a review [0.03%]
晚期非小细胞肺癌二、三线患者不可靶向突变患者的生存质量测量：综述
David Heigener,Thomas Küchler
David Heigener
Quality of life (QoL) is important to cancer patients and is increasingly included as a trial end point. The methodologies/findings of randomized controlled trials evaluating the efficacy and safety of second-line treatments approved for us...
Liquid biopsy and NSCLC [0.03%]
液体活检和非小细胞肺癌
Domenico Trombetta,Angelo Sparaneo,Federico Pio Fabrizio et al.
Domenico Trombetta et al.
In the era of high-throughput molecular screening and personalized medicine, difficulty in determining whether cancer mutations are truly 'actionable' remains a gray zone in NSCLC. The most important prerequisite to perform such investigati...
Targeting EGFR and ALK in NSCLC: current evidence and future perspective [0.03%]
NSCLC中EGFR和ALK的靶向治疗：现有证据及未来展望
Chiara Bennati,Luca Paglialunga,Biagio Ricciuti et al.
Chiara Bennati et al.
The advent of molecular therapy targeting specific driver oncogenes has dramatically changed the prognosis of a subset of NSCLC, dilating survival and improving the quality of life of patients with advanced disease. Two of the major targets...
Rebecca H Lehto
Rebecca H Lehto
Lung cancer is recognized to carry a high symptom burden with associated lowered quality of life as compared with other cancers. Research has shown that symptom severity can be a prognostic indicator of poorer clinical outcomes and survival...
Denis L Jardim,Debora de Melo Gagliato
Denis L Jardim
Andrea Viti,Alberto Terzi,Giuseppe Bogina et al.
Andrea Viti et al.